XML 81 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Acquisitions and Divestiture (Purchase Price Allocation) (Details) - USD ($)
$ in Millions
1 Months Ended 12 Months Ended
Jan. 22, 2021
Feb. 15, 2019
Jan. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Jun. 30, 2019
Business Acquisition [Line Items]              
Goodwill       $ 3,892.0 $ 3,766.5    
Cash paid, net of cash acquired       $ 747.4 $ 849.3 $ 6,917.7  
Prevail Therapeutics Inc.              
Business Acquisition [Line Items]              
Cash $ 90.5            
Acquired IPR&D 824.0            
Goodwill 126.8            
Deferred income taxes (106.0)            
Other assets and liabilities, net (31.5)            
Acquisition date fair value of consideration transferred 903.8            
Cash acquired (90.5)            
Fair value of CVR liability (65.9)            
Cash paid, net of cash acquired $ 747.4   $ 747.4        
Loxo Oncology, Inc.              
Business Acquisition [Line Items]              
Acquired IPR&D   $ 4,670.0          
Finite-lived intangibles   980.0          
Goodwill   2,326.9          
Deferred income taxes   (1,032.8)          
Other assets and liabilities, net   (26.4)          
Acquisition date fair value of consideration transferred   6,917.7          
Total identifiable net assets   $ 4,590.8          
Contract-based intangibles | Loxo Oncology, Inc.              
Business Acquisition [Line Items]              
Weighted average useful life   12 years          
Selpercatinib (LOXO-292) | Loxo Oncology, Inc.              
Business Acquisition [Line Items]              
Acquired IPR&D   $ 4,600.0         $ 4,600.0